Voting Common Stock, par value $0.0001 per share
- Symbol
- JSPR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Jasper Therapeutics, Inc.
JSPRNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On October 7, 2026, Jasper Therapeutics, Inc. (the “Company”) issued a press release announcing that it has commenced an offer to each holder of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), that were issued in the Company’s underwritten public offering on September 18, 2025 (the “Warrants”).…
Press release in this filing
Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants →Company context
Jasper is a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases. The company is advancing a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.
Current securities
Registered securities in this filing
JASPER THERAPEUTICS, INC. · 8-K · Filed 2026-10-07
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On October 7, 2026, Jasper
Therapeutics, Inc. (the “Company”) issued a press release announcing that it has commenced an offer to each holder of its outstanding
warrants to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), that were issued in the Company’s
underwritten public offering on September 18, 2025 (the “Warrants”). Under the offer, each holder may receive $0.324 in cash,
without interest, for each outstanding Warrant the holder tenders (the “Offer”). Each Warrant entitles its holder to purchase
one share of Common Stock at an exercise price of $2.92, subject to adjustment. As of October 6, 2026, 12,345,707 Warrants were outstanding.
The Offer is made only on
the terms and conditions set out in an Offer to Purchase, dated October 7, 2026, and other related offering materials that are being distributed
to holders of the Warrants. The Offer will be open until one minute after 11:59 p.m., Eastern Time, on November 6, 2026, or any later
date to which the Company may extend it. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated by reference
into this Item 8.01.
Filed exhibits (1)
Exhibit 99.1 Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants REDWOOD CITY, Calif., October 7, 2026 (GLOBE NEWSWIRE) - Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported that it has commenced an offer to purchase (the “Offer”) any and all of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the “Common Stock”), that were issued in its underwritten public offering on September 18, 2025 (the “Warrants”). The purchase price is $0.324 in cash per Warrant, without interest (the “Offer Purchase Price”). The purpose of the Offer is to reduce the number of shares of Common Stock that would become outstanding upon the exercise of the Warrants, thereby reducing the potential dilutive impact of the Warrants, and providing shareholders and prospective investors greater certainty as to the Company’s capital structure. Warrants tendered in the Offer will be retired and cancelled. Each Warrant lets its holder buy one share of Common Stock at an …
Open exhibit ↗